Pipeline Information
Learn more about our R&D pipeline and ongoing trials below
Development Programs – Solid Tumor
Drug
Indication
Phase 1
Phase 2
Phase 3
BGB-3245
(BRAF inhibitor)
Advanced solid tumors with BRAF mutations
Lifirafenib
(RAF inhibitor) + Mirdametinib (MEK inhibitor)
Advanced solid tumors
Tislelizumab + Ociperlimab
(anti-TIGIT)
1L PD-L1 high advanced NSCLC
2L PD-L1+ advanced ESCC
2L + cervical cancer
Advanced solid tumors
Tislelizumab + Ociperlimab + BAT1706
(anti-VEGF)
1L HCC
Tislelizumab + Ociperlimab + Chemotherapy
1L NSCLC
Tislelizumab + Ociperlimab + Concurrent Chemoradiotherapy
Previously untreated, stage III unresectable NSCLC
Previously untreated LS-SCLC
Pamiparib
(PARP 1-2 inhibitor)
2L/3L maintenance platinum-sensitive OC
1L maintenance platinum-sensitive GC
Advanced OC and TNBC
Pamiparib + Temozolomide
Advanced solid tumors
Tislelizumab
2L advanced ESCC
1L HCC
2L/3L NSCLC
Previously treated unresectable HCC
1L MSI-H or dMMR CRC
Previously treated advanced MSI-high or dMMR solid tumors
Tislelizumab + Surzebiclimab
(anti-TIM-3)
Advanced solid tumors
Tislelizumab + BGB-A445
(anti-OX40)
Advanced solid tumors
Tislelizumab + BGB-10188
(PI3K inhibitor)
Advanced solid tumors
Tislelizumab + BGB-15025
(HPK1 inhibitor)
Advanced solid tumors
Tislelizumab + Chemoradiotherapy
Localized ESCC
Tislelizumab + Chemotherapy/ Chemoradiotherapy
Resectable ESCC
Tislelizumab + Chemotherapy
1L advanced ESCC
1L GC/GEJC
Resectable stage II or IIIA NSCLC
1L advanced nasopharyngeal cancer
1L squamous NSCLC
1L non-squamous NSCLC
1L advanced UBC
1L ES-SCLC
Tislelizumab + DKN-01
(anti-DKK1) + Chemotherapy
1L/2L GC/GEJ
Tislelizumab + Fruquintinib
(VEGFR inhibitor)
Advanced or metastatic, unresectable GC, CRC, NSCLC
Advanced triple negative BC
Tislelizumab + Lenvatinib
(VEGFR kinase inhibitor)
1L HCC
Advanced solid tumors
Tislelizumab + Sitravatinib
(multikinase inhibitor)
Advanced NSCLC after anti-PD-(L)1 therapy
Advanced GC/GEJC/HCC
Advanced solid tumors
Tislelizumab + Surufatinib
(VEGFR, FGFR, CSF-1R inhibitor)
Advanced solid tumors
Zanidatamab
(anti-HER2 bi-specific antibody)
2L+ HER2+ BTC
Zanidatamab + Chemotherapy+/- Tislelizumab
1L HER2+ BC and 1L HER2+ GC/GEJC
1L HER2+ advanced/metastatic GC/EC
Australia
Australia, China
Australia, New Zealand
Australia, US
China
China, S. Korea
China, Thailand
S. Korea, US
United States
Worldwide
BC, breast cancer; BRAF, B-Raf proto-oncogene; BRCA+, breast cancer susceptibility gene-positive; BTC, biliary tract cancer; dMMR, deficient mismatch repair; ESCC, esophageal squamous cell carcinoma; ES-SCLC; extensive-stage small cell lung cancer; GBM, glioblastoma multiforme; GC, gastric cancer; GEJC, gastroesophageal junction carcinoma; HCC, hepatocelluar carcinoma; HER2-, human epidermal growth factor receptor-2–negative; HER2+, human epidermal growth factor receptor-2–positive; MSI, microsatellite instability; NSCLC, non-small cell lung cancer; OC, ovarian cancer; R/R, recurrent/refractory; SCLC, small lung cell cancer; TNBC, triple-negative breast cancer; UBC, urothelial bladder cancer.
Development Programs – Hematology
Drug
Indication
Phase 1
Phase 2
Phase 3
Tislelizumab
(anti-PD-1)
R/R cHL
R/R cHL
BGB-10188
(PI3K inhibitor) +/- Tislelizumab
B-cell malignancies
BGB-10188
(PI3K inhibitor) +/- Zanubrutinib (BTK inhibitor)
B-cell lymphoid malignancies
BGB-11417
(Bcl-2 inhibitor) monotherapy
B-cell malignancies
BGB-11417 + Azacitidine +/- Posaconazole
Myeloid malignancies
BGB-11417 + Dexamethasone +/- Carfilzomib
R/R multiple myeloma with t(11;14)
BGB-11417
monotherapy + zanubrutinib
B-cell malignancies
BGB-16673
(BTK-targeted CDAC)
B-cell malignancies
Zandelisib
(PI3K inhibitor) +/- Zanubrutinib or Rituximab*
CLL/SLL and B-cell NHL
Zanubrutinib
R/R CLL/SLL
1L and R/R WM
R/R MZL
Previously treated B-cell lymphoid malignancies
B-cell lymphoid malignancies
Zanubrutinib + Lenalidomide +/- Rituximab
R/R DLBCL
Zanubrutinib
+ Obinutuzumab (anti-CD20)
R/R FL
Zanubrutinib + Rituximab
(anti-CD20)
1L MCL
Zanubrutinib +/- Venetoclax†
(Bcl-2 inhibitor)
1L CLL/SLL
Australia
Australia, New Zealand
Australia, US
China
Japan
Switzerland, US
United States
Worldwide
* In collaboration with MEI Pharma
† This combination is being studied in the third cohort of NCT03336333
CDAC chimeric degradation activating compound; B-cell NHL, B-cell non-Hodgkins lymphoma; cHL, classical Hodgkin lymphoma; CLL, chronic lymphotic leukemia; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; GCB, germinal center B cell-like; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; NHL, non-Hodgkin lymphoma; NK, natural killer; R/R, recurrent/refractory; SLL, small lymphocytic lymphoma; WM, Waldenstrӧm macroglobulinemia.
Interactive Clinical Pipeline
Videos
PARPI Mechanism of Action
Anti-PD-1 Mechanism of Action
BTKI Mechanism of Action
Anti-TIGIT Mechanism of Action
